Reporter brief
Metformin tested in RCT to prevent frailty in high-risk older adults; results not reported
What happened
This abstract describes an RCT designed to test whether metformin prevents or reduces frailty progression in high-risk older adults by modulating diabetes, insulin resistance, and inflammation. No results, sample size, or effect sizes are provided in the available material.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
High-risk older adults; mean age 71-72 years; 48% female (68/141 at baseline); 93% White, 4% African American, 2% Other; 35% Hispanic or Latino
- Design
- Rct
- Sample
- 125
- Journal
- The University of Texas Health Science Center at San Antonio
- Published
- Oct 15, 2026
Effect size
Primary outcome - Metformin: 0.0289 (SE 0.0049); Placebo: 0.0164 (SE 0.0058). Secondary outcome - Metformin: -0.0002 (SE 0.0002); Placebo: 0.0002 (SE 0.0002)
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.